Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Thumbnail

UGA researchers find 27 new metabolites tied to arterial stiffness

Researchers at the University of Georgia have uncovered 27 new metabolites associated with arterial stiffness, according to work published in the American Journal of Hypertension.

FDA: Certain Medtronic pacemaker, CRT-P batteries can fail without warning

The FDA issued an alert May 7 warning patients with certain implanted Medtronic pacemakers or cardiac resynchronization therapy pacemakers (CRT-Ps) and their care teams to check for premature battery depletion in their devices after defects resulted in three reports and one patient death.

Thumbnail

CRT vs. RV pacing: Which is better for HFpEF patients?

Individuals with heart failure with preserved ejection fraction (HFpEF) and atrioventricular block might benefit more from cardiac resynchronization therapy (CRT) than conventional right ventricular (RV) pacing, according to research published in JACC: Heart Failure.

Thumbnail

Preemie heart damage could be reversed with exercise in young adulthood

Cardiac abnormalities stemming from preterm birth can be corrected with a three-and-a-half-month exercise program in patients’ teens and twenties, according to a drug-free trial of Canadian adults.

Thumbnail

Biotech startup aims to eradicate CAD with gene editing

A new biotech company out of Massachusetts is levering human genetics and genome editing to “turn the tide” of coronary artery disease (CAD), experimenting with CRISPR to stop CAD from ever developing in at-risk individuals.

FDA OKs Pfizer’s tafamidis to treat cardiac amyloidosis

The FDA has cleared two new drugs, tafamidis and tafamidis meglumine, for the treatment of cardiomyopathy caused by a rare disorder known as transthyretin-mediated amyloidosis (ATTR-CM).

Migraine drug shows no increase in CV outcomes

The migraine medication galcanezumab might protect against adverse CV events in patients taking the drug for episodic headaches, according to research presented at the American Academy of Neurology’s 2019 meeting in Philadelphia.

Thumbnail

ARB update: Vivimed issues 19-lot recall of losartan

Vivimed Life Sciences on May 3 announced a voluntary recall of 19 lots of losartan potassium tablets, making it the third company in two weeks to issue a recall of the blood pressure (BP) drug.